U.S., Dec. 2 -- ClinicalTrials.gov registry received information related to the study (NCT07256756) titled 'GC203 for Advanced Solid Tumors' on Nov. 20.
Brief Summary: This study is a prospective, open-label, single-arm clinical trial aimed at evaluating the safety and efficacy of GC203 TIL therapy in treating malignant solid tumors that have failed standard treatment.
Study Start Date: Nov. 30
Study Type: INTERVENTIONAL
Condition:
Solid Tumors, Adult
Intervention:
BIOLOGICAL: GC203 TIL
Engineered Tumor-Infiltrating Lymphocytes, GC203
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Shanghai Juncell Therapeutics
Disclaimer: Curated by HT Syndication....